|The PDL-1 n/a (Catalog #MBS592439) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Mouse monoclonal antibody to human PDL-1 reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s PDL-1 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB).
ELISA: Indirect ELISA: The antibody reacts with recombinant PDL-1 in indirect ELISA.
Western Blot: Anti-PDL-1 clone 12D9 detected 40ng recombinant PDL-1 on Western Blot. The blot was stained with HRP substrate 4-Chloro-1-Naphthol. Researchers should empirically determine the suitability of the PDL-1 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the Mouse monoclonal antibody to human PDL-1 with the following immunoassay(s):
Western Blot (WB)
Programmed Death Ligand-1 (PDL-1), a 40KD transmembrane protein, is a ligand of immune checkpoint protein Programmed Death-1 (PD-1). During T-cell receptor signalling, the binding of PDL-1 to PD-1 transmits an inhibitory signal to activated T-cells to decrease their proliferation. PDL-1 is also believed to play a role in the generation and regulation of Treg cells, and in the enhancement of Treg cell function. PDL-1/PD-1 pathway is important to immune suppression, such as self-tolerance, suppression of immune-rejection during pregnancy and allograft, and immune evasion by cancers. Upregulation of PD-L1 has been found to be associated with many cancer types. For example, increased PDL-1 expression has been shown to be related to tumor aggressiveness and higher mortality in patients with renal cell carcinoma, and related to significantly poorer prognosis and lower intraepithelial CD8+ T-lymphocyte count in patience with ovarian cancer. Antibodies that block the PDL-1 /PD-1 pathway have been extensively studied in clinical trials, and some have been approved as immunotherapy for cancer. .
Target Protein: Human programmed death ligand-1 (PDL-1), also known as B7H1 or CD274.
Immunogen: Human cell expressed recombinant PDL-1 (Phe19-Arg238) with poly-histidine tag at C-terminus. Fusion Myeloma: SP2/0
Reconstitution: Double distilled water is recommended to reconstitute the antibody to 1mg/mL. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing PDL-1 are readily searchable from our website. Different antibodies against the same target such as PDL-1 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.